ClinicalTrials.gg
TerminatedNCT04370522NIKOLEUpdated May 5, 2026

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

An observational study in Metastatic Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Terminated at 2 sites in Spain. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Spanish Breast Cancer Research Group · Observational

How we know

Why this study was terminated
Lack of funding to continue the research into Phase II

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Spanish Breast Cancer Research Group.

Enrollment
11th of 14
32 · median 271
Started
2021
with 1 other
Observational
14 of 49
3 open now
Registered
40th of 49
by date

Among the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, this one is the 11th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2021, is one of 14 observational ones, and was the 40th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, or all of them as a file.
02

Study summary

This is a multicentre, prospective, observational, no post-authorization study. This study will be opened for recruitment approximately for 12 months for a pilot phase including at least 25-30 patients and 6 controls and for 12 additional months to complete patient and control inclusion until 90 patients and 20 control depending on the first part study results.

Read the detailed description

After enrolment, patients will be assigned to one of the following cohorts according to their level of hormone-resistance:

  • Cohort A (hormone-sensitive disease).
  • Cohort B (hormone-resistant disease).

In both cohorts it will be collected residual pre-treatment tumor samples from metastatic lesions, preferably obtained after last treatment just prior to study entry, and/or primary breast tumor; as well as serial blood samples at baseline, after 6 weeks, at the same time of radiological re-evaluation (3 months after ET initiation) and at progressive disease (PD) which will be used for serial analytic determinations of the expression profiles of Natural Killer (NK) cells, other lymphoid innate cells, NKG2D ligands, cytokines and other possible biomarkers; in addition to obtain local data of hemogram and estradiol, Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels.

Patients who have participated in the study during their first line of ET are eligible to participate after progression, when they initiate the second line of ET (in this case, inclusion/exclusion criteria should be checked newly and Informed Consent Form (ICF) signed again).

From the control population it will be collected blood and local data (e.g. hemogram, estradiol, FSH and LH levels), in a single time-point after ICF signature.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Luminal
  • HER2 negative
  • Endocrine therapy resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Luminal/HER2 negative advanced Breast Cancer patients and a control group of healthy women (premenopausal and postmenopausal).

Eligibility criteria

INCLUSION AND EXCLUSION CRITERIA OF PATIENTS

Inclusion Criteria:

  1. Female ≥ 18 years of age on day of signing .
  2. Patient with histological confirmation of BC with evidence of or advanced disease not amenable to resection or radiation therapy with curative intent.
  3. Documented Hormonal Receptor (HR) positive status based on local testing (preferably assessed on the most recent tumour available). HR+ is defined as ≥ 1% positive cells by immuno-histochemistry (IHC) for ER and/or Progesterone Receptor (PgR).
  4. Documented negative status based on local testing (preferably assessed on the most recent tumour biopsy available). HER2- is defined as IHC score 0/1+ or negative by in situ hybridization according to local criteria.
  5. Patients who are going to receive ET in first or for advanced disease (in monotherapy or in combination). It is allowed the inclusion of patients that have received or are going to initiate tamoxifen, Luteinizing Hormone Releasing Hormone (LHRH) analogues, aromatase inhibitors or fulvestrant. It is also possible to recruit patients that have received or are going to initiate cyclin or mTOR inhibitors in combination with ET. (NOTE: it is not allowed the inclusion of patients after first line of chemotherapy that are in response and initiate maintenance ET).
  6. Patients who have participated in the study during their first line of ET are eligible to participate again when they receive the second line of ET (in this case eligibility criteria should be checked newly and ICF signed again).
  7. (ECOG) performance status (PS) 0-2.
  8. Patient must have a ≥ 16 weeks.
  9. The patient has signed and dated the ICF for study participation.
  10. Willingness and ability to comply with the protocol for the duration of the study including biological sample collection.

Exclusion Criteria:

  1. Have received more than 1 prior therapy line for advanced BC disease.
  2. Have received chemotherapy with response and initiate ET as maintenance treatment.
  3. Locally advanced breast cancer.
  4. Previous or concomitant treatment with immunotherapeutic agents.
  5. Major surgical procedure unrelated to breast cancer or significant traumatic injury within 28 days prior to study entry.
  6. History of concurrent or previously treated non-breast except for appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas, including cervix and colon.
  7. Has a diagnosis of immunodeficiency, disease or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of ET.
  8. Has an active infection requiring systemic therapy. Patients with solved infection that has finished antibiotic treatment within 7 days prior to study entry could be included.
  9. Has a known history of active Tuberculosis Bacillus (TB) or (HIV) (HIV 1/2 antibodies) or a known active (e.g., HBsAg reactive) or (HCV) (e.g. HCV RNA [qualitative] is detected).
  10. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  11. There is evidence that the patient is pregnant or breastfeeding, or patient is expecting to conceive within the projected duration of the study.
  12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator.

In the case of values of (NC) \< 1.5 x 109/L prior to study entry or in case of patients who have received or are going to receive an product, the information about NC or the investigational product should be checked with chief investigator in order to check any possible interference with the study results.

INCLUSION CRITERIA OF CONTROL PARTICIPANTS

  1. Female ≥ 18 years of age on day of signing informed consent.
  2. The participant has signed and dated the ICF for study participation.
  3. Absence of evidences of current tumor malignancies or active infectious disease.
  4. Absence of history or current evidences of immunological and rheumatologic diseases or any condition, therapy, or laboratory abnormality that might confound the results of the study, in the opinion of the investigator.
  5. Willingness and ability to comply with blood and study data collection.
  6. To have data to be able to be classified as pre- o .

Postmenopausal women are defined as women fulfilling any one of the following criteria (based on the National Comprehensive Cancer Network (NCCN) definition of menopause [NCCN 2008]):

  • Prior bilateral oophorectomy.
  • Age > 60 years.
  • Age ≤ 60 years and with amenorrhea for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and estradiol in the postmenopausal range.

Women who didn't comply with any of the prior criteria will be considered premenopausal women for the purposes of the study.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A: hormone-sensitive disease

    Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion. Patients will be divided in two subgroups according to having or not received previous ET.

  • Cohort B: hormone-resistant disease

    Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET: For first line: * Primary hormone-resistance: disease recurrence occurs within the first two years of adjuvant ET. * Secondary hormone-resistance: disease recurrence occurs after the first two years of adjuvant ET or during the first year after its completion. For second line: * Primary hormone-resistance: disease progression occurs within the first 6 months of ET for advanced disease. * Secondary hormone-resistance: disease progression occurs after the first 6 months of ET for advanced disease. Patients will be divided in two subgroups according to having primary or secondary hormone-resistance.

06

What researchers measure

Primary outcomes

  1. Amount of innate immune cells

    Amount of the different populations of innate immune cells (e.g. NK cells, ILC1, ILC2 and ILC3) detected in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry.

    Time frame: Up to disease progression, an average of 25 months

  2. Activation level of innate immune cells

    Activation level of the different populations of innate immune cells (e.g. NK cells, ILC1, ILC2 and ILC3) detected in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry.

    Time frame: Up to disease progression, an average of 25 months

  3. Analyses of the expression level of cytokines and/or rNKG2D ligands

    Analyses of the expression level of cytokines and/or rNKG2D ligands in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry.

    Time frame: Up to disease progression, an average of 25 months

Secondary outcomes

  1. Progression Free Survival (PFS) in relation with values of innate immune cells, cytokines and ligands of rNKG2D

    Progression Free Survival (PFS) defined as the time from the start of therapy to the first documented progressive disease, or death from any cause, whichever occurs first. Progressive disease will be based on the investigator's assessment according to the standard institutional guidelines, and following as much as possible RECIST version 1.1. Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1. every 3 months (+/- 1 month).

    Time frame: Up to disease progression, an average of 25 months

  2. Objective Response Rate (ORR) in relation with values of innate immune cells, cytokines and ligands of rNKG2D

    OR rate (ORR) is defined as the Complete Response (CR) + Partial Response (PR) out of the patients who had measurable disease at baseline, according to the standard institutional guidelines and following as much as possible the RECIST version 1.1. Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1. every 3 months (+/- 1 month).

    Time frame: Up to disease progression, an average of 25 months

  3. Clinical Benefit (CB) in relation with values of innate immune cells, cytokines and ligands of rNKG2D

    Clinical Benefit (CB): is defined as complete response (CR), partial response (PR), or stable disease (SD) lasting more than 24 weeks; based on the investigator's assessment according to the standard institutional guidelines, and following as much as possible according to the RECIST version 1.1. The definition of Response/non-Response and Stable Disease will be based on the RECIST version 1.1. Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1. every 3 months (+/- 1 month).

    Time frame: Up to disease progression, an average of 25 months

07

Study locations

2 sites
  • Hospital General Universitario Morales Meseguer
    Murcia, 30008, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Mar 2025, 46 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
May 1, 2020
StartActual
May 21, 2021
Primary completionActual
Mar 24, 2025
CompletionActual
Mar 24, 2025
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04370522
Lead sponsor
Spanish Breast Cancer Research Group
Responsible party
Sponsor
First posted
May 1, 2020
Start date
May 21, 2021
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025
Last update
May 5, 2026

Study contacts

Study Director
study director · Hospital General Universitario Morales Meseguer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion